Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 3, 2021-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials